2024-09-04
PM till aktieägare 2024-09-04
News 2024-08-09
PM Aktieägare 2024-08-08
Press release 2024-07-29
PM ISR 2024-07-27
News 2024-07-23
PM Aktieägare 2024-07-22 inkl. bilagor
News 2024-06-14
PM Aktieägare 2024-06-12 inkl. bilagor
News 2024-05-24
Brev till aktieägare 2024-05-24
News 2024-02-29
Extraordinary general meeting March 18th 2024
News 2024-02-23
Extra bolagsstämma 27 februari 2024 ställs in
News 2024-02-07
Brev till aktieägarna 2024-01-30
Press release 2023-08-28
ISR’s, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.
© ISR Immune System Regulation Holding AB (publ). All rights reserved.
Retzius väg 11
SE-171 65 Solna, Sweden
Email: info@isrholding.se
Phone: +46 708 24 53 00